27575716|t|PCSK9: Regulation and Target for Drug Development for Dyslipidemia
27575716|a|Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a secreted zymogen expressed primarily in the liver. PCSK9 circulates in plasma, binds to cell surface low-density lipoprotein (LDL) receptors, is internalized, and then targets the receptors to lysosomal degradation. Studies of naturally occurring PCSK9 gene variants that caused extreme plasma LDL cholesterol (LDL-C) deviations and altered atherosclerosis risk unleashed a torrent of biological and pharmacological research. Rapid progress in understanding the physiological regulation of PCSK9 was soon translated into commercially available biological inhibitors of PCSK9 that reduced LDL-C levels and likely also cardiovascular outcomes. Here we review the swift evolution of PCSK9 from novel gene to drug target, to animal and human testing, and finally to outcome trials and clinical applications. In addition, we explore how the genetics-guided path to PCSK9 inhibitor development exemplifies a new paradigm in pharmacology. Finally, we consider some potential challenges as PCSK9 inhibition becomes established in the clinic.
27575716	0	5	PCSK9	T116,T126	C4255394
27575716	7	17	Regulation	T044	C1327623
27575716	22	28	Target	T169	C1521840
27575716	33	49	Drug Development	T091	C0872152
27575716	54	66	Dyslipidemia	T047	C0242339
27575716	67	112	Proprotein convertase subtilisin/kexin type-9	T116,T126	C4255394
27575716	114	119	PCSK9	T116,T126	C4255394
27575716	126	134	secreted	T043	C1327616
27575716	135	142	zymogen	T116,T123	C0014436
27575716	170	175	liver	T023	C0023884
27575716	177	182	PCSK9	T116,T126	C4255394
27575716	197	203	plasma	T031	C0032105
27575716	205	226	binds to cell surface	T044	C1148628
27575716	227	266	low-density lipoprotein (LDL) receptors	T116,T192	C0034821
27575716	294	301	targets	T169	C1521840
27575716	306	315	receptors	T116,T192	C0597357
27575716	319	340	lysosomal degradation	T043	C4235415
27575716	373	383	PCSK9 gene	T028	C1426592
27575716	384	392	variants	T080	C0205419
27575716	413	419	plasma	T031	C0032105
27575716	420	435	LDL cholesterol	T109,T123	C0023824
27575716	437	442	LDL-C	T109,T123	C0023824
27575716	467	482	atherosclerosis	T047	C0004153
27575716	511	521	biological	T091	C0005532
27575716	526	541	pharmacological	T091	C0031330
27575716	542	550	research	T062	C0035168
27575716	588	601	physiological	T169	C0205463
27575716	602	612	regulation	T044	C1327623
27575716	616	621	PCSK9	T116,T126	C4255394
27575716	670	680	biological	T091	C0005532
27575716	681	700	inhibitors of PCSK9	T121	C4051515
27575716	714	719	LDL-C	T109,T123	C0023824
27575716	743	757	cardiovascular	T029	C3887460
27575716	787	802	swift evolution	T045	C3825184
27575716	806	811	PCSK9	T116,T126	C4255394
27575716	823	827	gene	T028	C0017337
27575716	831	835	drug	T121	C1254351
27575716	836	842	target	T169	C1521840
27575716	847	853	animal	T062	C1510899
27575716	858	863	human	T016	C0086418
27575716	864	871	testing	T062	C0013175
27575716	907	928	clinical applications	T062	C0008972
27575716	962	982	genetics-guided path	T058	C1948182
27575716	986	1001	PCSK9 inhibitor	T121	C4051515
27575716	1032	1040	paradigm	T062	C0681797
27575716	1044	1056	pharmacology	T091	C0031330
27575716	1108	1113	PCSK9	T116,T126	C4255394
27575716	1114	1124	inhibition	T039	C1524081
27575716	1152	1158	clinic	T073,T093	C0442592